Drug
Ataluren clinical trials
Also written PTC124 and Translarna.
- studies test it
- 32
- open now
- 0
- in phase 3
- 10
- first study started
- 2005
How studies write it
Studies that test it under each name
Studies by the year they started
32 studies that test it; most in 2010 (4)
| Year | Studies |
|---|---|
| 2005 | 3 |
| 2006 | 1 |
| 2007 | 1 |
| 2008 | 2 |
| 2009 | 3 |
| 2010 | 4 |
| 2012 | 1 |
| 2013 | 1 |
| 2014 | 3 |
| 2015 | 2 |
| 2016 | 3 |
| 2017 | 3 |
| 2018 | 2 |
| 2019 | 2 |
| 2021 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 2
- Phase 2
- 19
- Phase 3
- 10
- Phase 4
- 2
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 28 · Other 4
PTC Therapeutics (28) · University of Alabama at Birmingham (2) · NYU Langone Health (1) · Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) (1)
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses ataluren is read from its arms, and is right about nine times in ten.
Testing it · 32
- Study of Ataluren in Previously Treated Participants With Nonsense Mutation Dystrophinopathy (nmDBMD)TerminatedPhase 3PTC TherapeuticsNCT01247207Written as Ataluren
- Long-Term Outcomes of Ataluren in Duchenne Muscular DystrophyCompletedPhase 3PTC TherapeuticsNCT03179631Written as Ataluren
- A Study to Evaluate the Safety and Pharmacokinetics of Ataluren in Participants From ≥6 Months to <2 Years of Age With Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD)CompletedPhase 2PTC TherapeuticsNCT04336826Written as Ataluren
- Ataluren for Nonsense Mutation in CDKL5 and Dravet SyndromeCompletedPhase 2NYU Langone HealthNCT02758626Written as ataluren
- Pembrolizumab With Ataluren in Patients With Metastatic pMMR and dMMR Colorectal Carcinoma or Metastatic dMMR Endometrial Carcinoma: the ATAPEMBRO StudyStatus unknownPhase 1/2Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)NCT04014530Written as Ataluren + Pembrolizumab
- Study of Ataluren in Participants With Nonsense Mutation AniridiaCompletedPhase 2PTC TherapeuticsNCT02647359Written as Ataluren
- A Study to Assess Dystrophin Levels in Participants With Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD)CompletedPhase 2PTC TherapeuticsNCT03648827Written as Ataluren
- A Study to Assess Dystrophin Levels in Participants With Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD) Who Have Been Treated With AtalurenCompletedPhase 2PTC TherapeuticsNCT03796637Written as Ataluren
- Study of Ataluren for Previously Treated Participants With Nonsense Mutation Duchenne/Becker Muscular Dystrophy (nmDBMD) in Europe, Israel, Australia, and CanadaCompletedPhase 3PTC TherapeuticsNCT01557400Written as Ataluren
- Phase 2a Extension Study of Ataluren (PTC124) in Duchenne Muscular Dystrophy (DMD)TerminatedPhase 2PTC TherapeuticsNCT00759876Written as Ataluren
- Extension Study of Ataluren (PTC124) in Cystic FibrosisCompletedPhase 3PTC TherapeuticsNCT01140451Written as Ataluren
- Study of Ataluren in ≥2 to <5 Year-Old Male Participants With Duchenne Muscular DystrophyCompletedPhase 2PTC TherapeuticsNCT02819557Written as Ataluren
- An Extension Study of Ataluren (PTC124) in Participants With Nonsense Mutation DystrophinopathyTerminatedPhase 3PTC TherapeuticsNCT02090959Written as Ataluren
- Phase 3 Study of Ataluren in Participants With Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD)CompletedPhase 3PTC TherapeuticsNCT01826487Written as Ataluren
- Study of Ataluren (PTC124) in Nonambulatory Participants With Nonsense-Mutation-Mediated Duchenne/Becker Muscular Dystrophy (nmDMD/BMD)TerminatedPhase 2PTC TherapeuticsNCT01009294Written as Ataluren
- Phase 2B Extension Study of Ataluren (PTC124) in Duchenne/Becker Muscular Dystrophy (DMD/BMD)TerminatedPhase 2PTC TherapeuticsNCT00847379Written as Ataluren
- Ataluren for Nonsense Mutation Methylmalonic AcidemiaTerminatedPhase 2PTC TherapeuticsNCT01141075Written as Ataluren
- Study of Ataluren (PTC124) in Hemophilia A and BTerminatedPhase 2PTC TherapeuticsNCT00947193Written as Ataluren
- Safety and Efficacy of Ataluren (PTC124) for Cystic FibrosisCompletedPhase 2PTC TherapeuticsNCT00237380Written as Ataluren
- Study of Ataluren in Nonsense Mutation Cystic Fibrosis (ACT CF)CompletedPhase 3PTC TherapeuticsNCT02139306Written as Ataluren (PTC124®)
Codes
What other systems call ataluren · ClinicalTrials.gg INT005016
- MeSH (NLM) C515878atalurenOne source NLM
- UNII (FDA) K16AME9I3VATALURENConfirmed FDA, NLM, Wikidata
- Wikidata Q753330atalurenConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C169791AtalurenOne source FDA
- DrugBank DB05016One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C515878 | ataluren | One source NLM |
| UNII (FDA) | K16AME9I3V | ATALUREN | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q753330 | ataluren | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C169791 | Ataluren | One source FDA |
| DrugBank | DB05016 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.